EcoR1 Capital LLC Has $7.73 Million Stock Holdings in Metsera Inc. $MTSR

EcoR1 Capital LLC increased its holdings in shares of Metsera Inc. (NASDAQ:MTSR) by 443.1% in the second quarter, Holdings Channel.com reports. The firm owned 271,529 shares of the company’s stock after purchasing an additional 221,529 shares during the quarter. Metsera makes up 0.5% of EcoR1 Capital LLC’s holdings, making the stock its 28th largest holding. EcoR1 Capital LLC’s holdings in Metsera were worth $7,725,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of MTSR. BNP Paribas Financial Markets lifted its stake in Metsera by 100.0% in the second quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock valued at $46,000 after buying an additional 800 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Metsera by 32.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 4,293 shares of the company’s stock worth $122,000 after acquiring an additional 1,056 shares during the period. Prudential Financial Inc. lifted its position in Metsera by 7.9% in the 2nd quarter. Prudential Financial Inc. now owns 16,070 shares of the company’s stock valued at $457,000 after acquiring an additional 1,170 shares in the last quarter. New York State Common Retirement Fund lifted its position in Metsera by 25.0% in the 2nd quarter. New York State Common Retirement Fund now owns 6,000 shares of the company’s stock valued at $171,000 after acquiring an additional 1,200 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Metsera by 0.5% in the 2nd quarter. American Century Companies Inc. now owns 287,674 shares of the company’s stock worth $8,184,000 after purchasing an additional 1,467 shares during the period.

Analyst Ratings Changes

Several analysts have issued reports on the company. Leerink Partnrs downgraded Metsera from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Metsera in a report on Wednesday, September 3rd. Leerink Partners reissued a “market perform” rating and issued a $57.00 target price (down previously from $77.00) on shares of Metsera in a research report on Wednesday, September 24th. Weiss Ratings restated a “sell (d)” rating on shares of Metsera in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Metsera from a “sell” rating to a “hold” rating in a research report on Wednesday, October 1st. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Metsera has a consensus rating of “Hold” and a consensus price target of $55.75.

Metsera Price Performance

Shares of NASDAQ MTSR opened at $70.50 on Friday. The business has a 50-day moving average of $64.17 and a 200-day moving average of $45.24. The stock has a market capitalization of $7.42 billion and a price-to-earnings ratio of -11.16. Metsera Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $83.86.

Metsera (NASDAQ:MTSR) last released its earnings results on Wednesday, November 12th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.55).

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.